CL2019002145A1 - Composición farmacéutica que comprende betahistina. - Google Patents

Composición farmacéutica que comprende betahistina.

Info

Publication number
CL2019002145A1
CL2019002145A1 CL2019002145A CL2019002145A CL2019002145A1 CL 2019002145 A1 CL2019002145 A1 CL 2019002145A1 CL 2019002145 A CL2019002145 A CL 2019002145A CL 2019002145 A CL2019002145 A CL 2019002145A CL 2019002145 A1 CL2019002145 A1 CL 2019002145A1
Authority
CL
Chile
Prior art keywords
betahistine
pharmaceutical composition
neurological
treatment
pharmaceutically acceptable
Prior art date
Application number
CL2019002145A
Other languages
English (en)
Inventor
Christopher John Wraight
Thomas Meyer
Original Assignee
Otolanum Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otolanum Ag filed Critical Otolanum Ag
Publication of CL2019002145A1 publication Critical patent/CL2019002145A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE, COMO SUSTANCIA ACTIVA, BETAHISTINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTA, PARA SU USO EN EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS U OTOLÓGICOS EN UN SUJETO HUMANO MEDIANTE APLICACIÓN INTRANASAL.
CL2019002145A 2017-02-02 2019-07-30 Composición farmacéutica que comprende betahistina. CL2019002145A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762453931P 2017-02-02 2017-02-02

Publications (1)

Publication Number Publication Date
CL2019002145A1 true CL2019002145A1 (es) 2019-11-04

Family

ID=61187302

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002145A CL2019002145A1 (es) 2017-02-02 2019-07-30 Composición farmacéutica que comprende betahistina.

Country Status (33)

Country Link
US (2) US10456386B2 (es)
EP (2) EP3698791B1 (es)
JP (3) JP7714323B2 (es)
KR (1) KR102653545B1 (es)
CN (2) CN118356397A (es)
AR (1) AR111699A1 (es)
AU (1) AU2018216970B2 (es)
CA (1) CA3051725A1 (es)
CL (1) CL2019002145A1 (es)
CO (1) CO2019008657A2 (es)
DK (2) DK3474850T3 (es)
EA (1) EA201991817A1 (es)
ES (2) ES2969301T3 (es)
FI (1) FI3698791T3 (es)
HR (2) HRP20231706T1 (es)
HU (2) HUE050829T2 (es)
IL (1) IL268353B2 (es)
LT (2) LT3474850T (es)
MA (1) MA46778B1 (es)
MX (1) MX381932B (es)
MY (1) MY196333A (es)
NZ (1) NZ755931A (es)
PH (1) PH12019501785B1 (es)
PL (2) PL3474850T3 (es)
PT (2) PT3474850T (es)
RS (2) RS60554B1 (es)
SA (1) SA519402324B1 (es)
SG (1) SG11201906980YA (es)
SI (2) SI3698791T1 (es)
TN (1) TN2019000220A1 (es)
TW (1) TWI760429B (es)
WO (1) WO2018141922A1 (es)
ZA (1) ZA201904955B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170532A1 (en) * 2017-03-22 2018-09-27 Franz, Lilian Ann Treatment method
WO2021211504A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Nasal spray formulation with moisturizing benefits
US20240165151A1 (en) * 2020-04-22 2024-05-23 Sanotize Research And Development Corp. Compositions and methods for treating upper respiratory infections
WO2026062705A1 (en) 2024-09-23 2026-03-26 Troikaa Pharmaceuticals Limited Oromucosal liquid compositions of betahistine or its pharmaceutically acceptable salt(s) and processes for preparation thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397840B1 (es) 1977-07-22 1981-03-20 Cherqui Jean
IT1229237B (it) * 1989-05-08 1991-07-26 Prodotti Formenti Sali di (2-(piridil)etil) metilammina
JPH03287535A (ja) * 1990-03-31 1991-12-18 Bairon Boeki Kk プラノプロフェン水溶液
JP3203056B2 (ja) * 1992-08-13 2001-08-27 株式会社ティ・ティ・エス技術研究所 メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
JPH10139667A (ja) * 1996-11-15 1998-05-26 Yoshitomi Pharmaceut Ind Ltd 水性液剤
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
JP3555598B2 (ja) 2001-06-27 2004-08-18 株式会社村田製作所 積層型インダクタ
JP2004196676A (ja) * 2002-12-16 2004-07-15 Rohto Pharmaceut Co Ltd 点鼻剤
JP4733333B2 (ja) * 2002-12-26 2011-07-27 ライオン株式会社 点鼻剤又は洗鼻剤
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
AU2006202950A1 (en) * 2004-04-22 2006-10-19 Mor Research Applications Ltd. Methods and Compositions for Weight Management
US7728015B2 (en) * 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
BRPI0506807A (pt) * 2004-04-22 2007-05-29 Mor Research Applic Ltd método de gerenciamento de consumo de alimento e composição farmacológica
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
US8119668B2 (en) * 2005-12-23 2012-02-21 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US8242148B2 (en) * 2005-12-23 2012-08-14 Nelson Erik B Treatment methods employing histamine H3 receptor antagonists, including betahistine
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
WO2009086055A1 (en) * 2007-12-21 2009-07-09 Schering-Plough Healthcare Products, Inc. Enhancing photostabilization of oxymetazoline
KR20130097813A (ko) * 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
KR101621726B1 (ko) * 2008-05-27 2016-05-17 더 유니버시티 오브 멜버른 유스타키오관 기능장애 치료용 국소 약학적 조성물
CN105330603A (zh) * 2008-10-08 2016-02-17 凯飞药业公司 Gaba偶联物及其使用方法
JP2017530195A (ja) * 2014-10-03 2017-10-12 ラケシス・バイオサイエンシーズ・リミテッド 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物

Also Published As

Publication number Publication date
KR102653545B1 (ko) 2024-04-04
HRP20231706T1 (hr) 2024-03-15
CN110418643A (zh) 2019-11-05
PL3474850T3 (pl) 2020-09-21
NZ755931A (en) 2022-07-29
EP3698791B1 (en) 2023-10-25
JP2020506930A (ja) 2020-03-05
CO2019008657A2 (es) 2020-01-17
US20180214432A1 (en) 2018-08-02
LT3474850T (lt) 2020-08-10
EP3474850A1 (en) 2019-05-01
SI3474850T1 (sl) 2020-09-30
MA46778B1 (fr) 2022-08-31
PH12019501785B1 (en) 2024-02-28
MX2019008961A (es) 2019-10-15
MX381932B (es) 2025-03-13
WO2018141922A1 (en) 2018-08-09
HUE050829T2 (hu) 2021-01-28
EA201991817A1 (ru) 2020-01-27
PT3474850T (pt) 2020-07-27
ES2807798T3 (es) 2021-02-24
ES2969301T3 (es) 2024-05-17
SI3698791T1 (sl) 2024-05-31
HRP20201137T1 (hr) 2021-01-22
AU2018216970B2 (en) 2023-12-21
JP2022051872A (ja) 2022-04-01
RS65099B1 (sr) 2024-02-29
EP3474850B1 (en) 2020-04-22
PH12019501785A1 (en) 2020-07-06
IL268353B1 (en) 2023-06-01
TN2019000220A1 (en) 2021-01-07
PT3698791T (pt) 2024-01-12
DK3698791T3 (da) 2024-01-15
CA3051725A1 (en) 2018-08-09
MY196333A (en) 2023-03-24
HUE065336T2 (hu) 2024-05-28
KR20190116341A (ko) 2019-10-14
MA46778A1 (fr) 2021-04-30
DK3474850T3 (da) 2020-08-03
SA519402324B1 (ar) 2023-03-16
AU2018216970A1 (en) 2019-08-22
EP3698791A1 (en) 2020-08-26
TWI760429B (zh) 2022-04-11
IL268353B2 (en) 2023-10-01
BR112019015687A2 (pt) 2020-04-28
PL3698791T3 (pl) 2024-04-08
IL268353A (en) 2019-09-26
US10456386B2 (en) 2019-10-29
RS60554B1 (sr) 2020-08-31
CN118356397A (zh) 2024-07-19
JP2024019731A (ja) 2024-02-09
US20200022963A1 (en) 2020-01-23
JP7714323B2 (ja) 2025-07-29
AR111699A1 (es) 2019-08-14
LT3698791T (lt) 2024-02-12
TW201831179A (zh) 2018-09-01
SG11201906980YA (en) 2019-08-27
ZA201904955B (en) 2021-05-26
FI3698791T3 (fi) 2024-01-11

Similar Documents

Publication Publication Date Title
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
CL2016001895A1 (es) Compuestos
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
MX2015003140A (es) Formulaciones de enzalutamida.
PE20160052A1 (es) Composicion farmaceutica de clorhidrato de s-cetamina
PE20151157A1 (es) Formas de dosificacion de ruxolitinib de liberacion sostenida
CL2019002145A1 (es) Composición farmacéutica que comprende betahistina.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY37379A (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
CL2015002835A1 (es) Nuevos derivados de piridina
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
AR094241A1 (es) Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.